今日涨跌幅居前的概念板块 截至7月29日收盘，CRO概念上涨4.00%，位居概念板块涨幅第1，板块内，61股上涨，睿智医药20%涨 停，奥翔药业、九洲药业等涨停，药石科技、海特生物、昭衍新药等涨幅居前，分别上涨18.77%、 15.28%、9.94%。跌幅居前的有亨迪药业、东方海洋、河化股份等，分别下跌1.64%、1.36%、1.22%。 CRO概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 603456 | 九洲药 业 | 10.01 | 12.54 | 24987.61 | 11.64 | | 300149 | 睿智医 药 | 20.02 | 24.95 | 23482.56 | 15.31 | | 688222 | 成都先 导 | 4.13 | 10.29 | 15713.53 | 16.19 | | 300759 | 康龙化 成 | 6.49 | 7.54 | 14552.85 | 4.28 | ...

截至7月29日收盘，创新药概念上涨2.79%，位居概念板块涨幅第3，板块内，195股上涨，睿智医药20% 涨停，奥翔药业、亚太药业、九洲药业等涨停，三元基因、药石科技、南新制药等涨幅居前，分别上涨 20.76%、18.77%、17.01%。跌幅居前的有昂利康、*ST苏吴、多瑞医药等，分别下跌6.16%、5.04%、 4.66%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002173 | 创新医疗 | 14.25 | -2.40% | 30.64万 | 4.38亿 | | 600568 | ST中珠 | 1.71 | -1.16% | 25.07万 | 4270.89万 | | 301060 | 兰卫医学 | 10.88 | -0.91% | 15.48万 | 1.68 Z | | 002622 | 皓宸医疗 | 3.08 | -0.65% | 19.90万 | 6122.15万 | | 835670 | 数字人 | 15.01 | -0.27% | 2.46万 | 3694.46万 | | 002172 | 澳洋健康 | 4.04 | -0.25% | 76.58万 | 3.11亿 | | 301293 | 三博脑科 | 48.88 | -0.10% | 6.96万 | 3.37亿 | | 300143 | 宮康生命 | 10.13 | 0.10% | 9.68万 | 9742.32万 | | 002044 | ...

| 代码 | 名称 | 涨幅+ | 现价 | | --- | --- | --- | --- | | 837344 | 三元基因 | +20.76% | 34.84 | | 300149 | 雪智医药 | +20.02% | 13.61 | | 300725 | 药石科技 | +18.77% | 53.10 | | 688189 | 图新制药 | +17.01% | 11.90 | | 688513 | 苑东生物 | +15.45% | 65.92 | | 300683 | 海特生物 | +15.28% | 50.61 | | 688321 | 微芯生物 | +12.85% | 38.37 | | 430047 | 诺思兰德 | +11.14% | 25.25 | | 603229 | 奥翔药业 | +10.02% | 10.54 | | 002370 | 亚太药业 | +10.02% | 6.81 | | 603367 | 辰欣药业 | +10.01% | 25.93 | | 603456 | 九洲药业 | +10.01% | 19.68 | | 601089 | 福元医药 | 49.99% | 22.90 ...

7月29日，A股三大指数继续上涨，深成指、创业板指创去年11月以来新高。 截至收盘，沪指涨0.33%报3609点，深证成指涨0.64%，创业板指涨1.86%报2406点。 全天成交1.83万亿元，较前一交易日增量632亿元，全市场超3000股下跌。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 上证指数 | Shorton | 3609.71 | +11.77 | +0.33% | | 000001 | | | | | | 创业板指 | | 2406.59 | +44.00 | +1.86% | | 399006 | | | | | | 深证成指 | | 11289.41 | +71.82 | +0.64% | | 1000001 | | | | | 盘面上，CRO、创新药板块爆发，CPO、钢铁板块活跃；化学制药、F5G概念、雅下水电及半导体等板块涨幅居前。另外，保险板块走低，猪 肉、鸡肉概念走弱，银行、PEEK材料及石油等板块跌幅居前。 具体来看： CRO概念、创新药领涨大市，睿智医药、奥翔药业、亚太药业、九州药业等多股涨停。消息面 ...

Market Overview - The three major A-share indices all rose, with the Shanghai Composite Index up 0.33%, the Shenzhen Component Index up 0.64%, and the ChiNext Index up 1.86% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.8293 trillion yuan, an increase of 63.2 billion yuan compared to the previous day [1] - Over 2,200 stocks in the two markets experienced gains [1] Sector Performance - The CRO (Contract Research Organization), special steel, and hydropower sectors saw significant gains, while the banking, insurance, and pork sectors experienced declines [2] - The CRO sector performed strongly, with stocks like Ruizhi Pharmaceutical and Aoxiang Pharmaceutical hitting the daily limit, and others like Yaoshi Technology and Hitec Bio rising over 17% [2] - The special steel sector rebounded, with Xining Special Steel and Bayi Iron & Steel reaching the daily limit [2] - The hydropower sector also saw a rebound, with stocks like Shen Shui Gui Yuan hitting the daily limit [2] - The banking sector declined across the board, with no stocks in the sector rising [2] - The insurance sector adjusted, with companies like New China Life and China Pacific Insurance falling over 1% [2] - The pork sector saw declines, with Shennong Group dropping over 7% [2] Notable Stocks - The strongest stock on the limit-up board was Tibet Tourism, which achieved a 7-day consecutive limit-up [3] - Other notable stocks with consecutive limit-ups included Huaci Co., Ltd. and Shanhe Intelligent [3] Hot Sectors - The Huawei concept sector was the strongest, with 9 stocks hitting the daily limit and 3 stocks achieving consecutive limit-ups [4] - The innovative drug sector had 8 stocks hitting the daily limit, with 2 stocks achieving consecutive limit-ups [5] - The consumer electronics sector had 7 stocks hitting the daily limit, with 3 stocks achieving consecutive limit-ups [6] Current Market Trends - The humanoid robot sector is gaining attention, with related stocks like Haichang New Materials and Xiangxin Technology benefiting from new policies promoting AI applications in Shanghai [9] - The water conservancy sector is also in focus due to recent heavy rainfall causing significant flooding in multiple regions, with stocks like Jikang Technology and Shen Shui Gui Yuan being relevant [10] - The AI agent sector is highlighted by the release of a new flagship model by Zhipu AI, which is designed for intelligent applications [11]

Core Viewpoint - The pharmaceutical sector is experiencing a significant surge, particularly in the areas of CRO (Contract Research Organization) and innovative drugs, with many companies reporting strong mid-year earnings and profit forecasts [5][9]. Market Performance - The A-share market saw a mixed performance with the ChiNext index rising by 0.92%, while the Shanghai Composite Index and Shenzhen Component Index fell slightly by 0.08% and 0.04% respectively [2]. - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.13 trillion yuan, an increase of 67 billion yuan compared to the previous day [2]. Sector Highlights - The pharmaceutical sector, including CRO, innovative drugs, weight loss drugs, and generic drugs, showed strong performance with CRO stocks rising by 5.7%, innovative drugs by 2.91%, weight loss drugs by 2.46%, and generic drugs by 2.17% [3][6]. - Conversely, the agricultural sector and several other industries such as daily chemicals, fertilizers, and petrochemicals experienced declines [2]. Individual Stock Performance - Notable individual stock performances included: - Zhaoyan New Drug rising by 16.31% - Microchip Biotech increasing by 13.29% - Jiuzhou Pharmaceutical hitting the daily limit [6]. - WuXi AppTec saw its H-shares rise by 10.56% and A-shares by 6.3%, following the announcement of a 20.64% year-on-year increase in revenue to 20.8 billion yuan and a 101.92% increase in net profit [8]. Earnings Forecasts - Many pharmaceutical companies are projecting strong earnings for the first half of 2025, with some expecting profit increases of over 400% [9]. - WuXi AppTec has adjusted its revenue growth forecast for its ongoing business from 10%-15% to 13%-17%, with total revenue expectations revised from 41.5 billion to 43.5 billion yuan [8].

Market Overview - A-shares showed mixed performance on July 24, with the Shanghai Composite Index down 0.02%, while the Shenzhen Component Index rose by 0.37% and the ChiNext Index increased by 0.77% [1] - The Hainan Free Trade Zone concept stocks were notably active, with companies like Caesar Travel hitting the daily limit [1] - The biopharmaceutical sector, including fentanyl and monkeypox concepts, showed strength, with stocks like Wanfeng Biological and Botao Biological rising [1] - The rare earth permanent magnet sector also saw renewed activity, with Zhongke Sanhuan hitting the daily limit [1] - Conversely, sectors such as large financials, precious metals, steel, photovoltaic, and power grid equipment experienced declines [1] Sector Insights Biopharmaceutical Sector - The biopharmaceutical sector is active, with significant movements in stocks related to fentanyl and CRO, including Wanfeng Biological and Chengdu Xian Dao [1][2] - CITIC Securities noted that recent policies supporting the high-quality development of innovative drugs are positively impacting the sector, enhancing the international competitiveness of domestic innovative drug companies [1] Financial Sector - Huatai Securities indicated a strong willingness among investors to buy, suggesting that even during market dips, funds quickly enter the market [3] - The financial sector is seen as a key player in the ongoing market rotation, contributing to the upward trend of the index [5] Cyclical Stocks - Xinda Securities highlighted the recent performance of previously underperforming cyclical sectors such as photovoltaic, steel, and chemicals, suggesting this may signal the bull market entering a mid-stage rally [4] - The valuation advantage of cyclical stocks is expected to become more pronounced as the bull market progresses, especially with potential policy catalysts or improvements in fundamentals [4] Traditional and Tech Industries - According to Dongfang Securities, traditional industries and the broader tech sector are expected to play a crucial role in supporting market growth [5] - The continuous positive feedback from daily gains is building market confidence, with the Shanghai Composite Index potentially breaking past significant resistance levels [5]

上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 Suite 45/F, K.Wah Centre, 1010 Huaihai Road (M), Xuhui District, Shanghai, China T: (86-21) 5404 9930 F: (86-21) 5404 9931 北京市竞天公诚律师事务所上海分所 关于 睿智医药科技股份有限公司 2025 年限制性股票激励计划调整及首次授予事项之 法律意见书 二〇二五年七月 北京 · 上海 · 深圳 · 成都 · 南京 · 杭州 · 广州 · 三亚 · 香港 Beijing·Shanghai·Shenzhen·Chengdu·Nanjing·Hangzhou·Guangzhou·Sanya·Hong Kong 北京市竞天公诚律师事务所上海分所 关于睿智医药科技股份有限公司 2025 年限制性股票激励计划调整及首次授予事项之 法律意见书 致：睿智医药科技股份有限公司 本所接受睿智医药的委托，根据《公司法》《证券法》《管理办法》等有关 法律、法规、规章及规范性文件的规定，已就公司本次激励计划的相关事项出具 了《北京市竞天公诚律 ...

（授予日） 一、激励对象获授的限制性股票分配情况 睿智医药科技股份有限公司 2025 年限制性股票激励计划首次授予激励对象名单 本激励计划首次授予的限制性股票在各激励对象间的分配情况如下表所示： 2025 年 7 月 11 日 1 2、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 睿智医药科技股份有限公司 | | | | | 获授的限制性股 | 占授予限制 | 占目前总 | | --- | --- | --- | --- | --- | --- | --- | | 序号 | 姓名 | 国籍 | 职务 | 票数量 | 性股票总数 | 股本的比 | | | | | | （万股） | 的比例 | 例 | | 1 | 樊世新 | 中国 | 董事 | 180.00 | 3.42% | 0.36% | | 2 | 陈旺龙 | 中国 | 董事、副总裁 | 150.00 | 2.85% | 0.30% | | 3 | 查胤群 | 中国 | 首席财务官 | 100.00 | 1.90% | 0.20% | | 4 | 许剑 | 中国 | 董事会秘书 | 100.00 | 1.90% | 0.20% | ...